Stock comparison
Mettler-Toledo International
Takeda Pharmaceutical Company Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
TAK
Takeda Pharmaceutical Company Limited
Market cap
$51.34B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | TAK | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 44D | MTD |
| Benjamin Graham | 65B | 56C | MTD |
| Philip Fisher | 63C | 40D | MTD |
| Peter Lynch | 66B | 18F | MTD |
| Joel Greenblatt | 68B | 32F | MTD |
| Charlie Munger | 74B | 41D | MTD |
| Terry Smith | 70B | 36D | MTD |
Side-by-side metrics
| Metric | MTD | TAK |
|---|---|---|
| Market cap | $22.29B | $51.34B |
| P/E (TTM) | 25.3x | 43.0x |
| EV/EBIT | 21.6x | 22.0x |
| ROIC (TTM) | 36.09% | 2.59% |
| Gross margin | 57.79% | 58.76% |
| Net margin | 21.4% | 4.26% |
| Revenue CAGR 5y | 2.01% | 7.56% |
| EPS CAGR 5y | 6.12% | -3.46% |
| Debt / Equity | - | 0.6x |
| Dividend yield | 0.0% | 3.79% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- EPS CAGR 5y6.12%vs -3.46%+156%
- Debt / Equity-vs 0.6x+101%
- ROIC (TTM)36.09%vs 2.59%+93%
- Net margin21.4%vs 4.26%+80%
TAK leads on
- Dividend yield3.79%vs 0.0%+100%
- Revenue CAGR 5y7.56%vs 2.01%+73%
- Market cap$51.34Bvs $22.29B+57%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.